Clinical฀setbacks฀for฀toll-like฀ receptor฀9฀agonists฀in฀cancer Page 1 NATURE฀BIOTECHNOLOGY฀฀฀VOLUME฀25฀฀฀NUMBER฀8฀฀฀AUGUST฀2007฀
825 Clinical฀setbacks฀for฀toll-like฀ receptor฀9฀agonists฀in฀cancer In฀June,฀Pfizer฀dropped฀a฀clinical฀program฀in฀
non-small฀cell฀lung฀cancer฀for฀PF-3512676,฀a฀ CpG฀oligodeoxynucleotide฀(ODN)฀drug฀that฀
activated฀toll-like฀receptor฀9฀(TLR9)฀of฀the฀ immune฀system.฀While฀being฀tested฀in฀phase฀2฀
and฀3฀trials฀together฀with฀a฀variety฀of฀chemotherapy฀agents,฀an฀interim฀analysis฀of฀the฀two฀
phase฀3฀trials฀of฀PF-3512676฀showed฀it฀failed฀ to฀yield฀clinical฀outcomes฀better฀than฀those฀ …